The EULAR data are the primary catalyst. If the late-breaking oral confirms the 71% ACR50 with deep B-cell depletion comparable to CAR T, the thesis of an 'off-the-shelf' alternative to CAR T in autoimmune indications strengthens materially. Monitor the webcast on June 8 and feedback from key opinion leaders. The Phase 3 initiation in 2026 is a major milestone derisking event — if the data are consistent, expect upward re-rating. Risk: interim small-sample data (31 patients) may not replicate in pivotal trials; competitive landscape with other NK and CAR T autoimmune programs.
Price Chart
Executive Summary
Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB-101) allogeneic NK cell therapy in autoimmune diseases. A late-breaking oral abstract showed 71% ACR50 response in refractory RA patients with ≥6-month follow-up, no relapses, and B-cell depletion comparable to autologous CD19 CAR T therapy. The company plans a Phase 3 registrational trial in refractory RA in 2026. This is a significant clinical data catalyst for a clinical-stage biotech — the data are early and interim but the CAR T comparability claim and refractory RA response rates are the key bullish signals.
Key Facts
- Five abstracts accepted at EULAR 2026, including one late-breaking oral presentation.
- Late-breaking abstract (LB0003): 71% ACR50 response in refractory RA patients with ≥6-month follow-up; zero relapses or new immunomodulatory agents required.
- First patient with severe Sjögren disease treated with AlloNK + rituximab showed positive experience (abstract OP0129).
- Data claim B-cell depletion comparable to autologous CD19 CAR T therapies (abstracts POS0355, AB0345).
- AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy.
- Company plans to initiate a Phase 3 registrational trial in refractory RA in 2026.
- Live post-meeting webcast with KOL Dr. Paul Emery scheduled for June 8, 2026 at 8:15 am EDT.
- Market cap ~$228M, 92% analyst buy rating, $100M insider purchases in last 30 days.
Financial Impact
No financial data provided in press release. Artiva is pre-revenue clinical-stage (no revenue, no EPS). Market cap ~$228M. Insider purchases totalling $100M in 30 days signal strong confidence. If AlloNK progresses to approval in refractory RA (large market opportunity — RA biologics market >$25B globally), the value inflection is substantial.
Risk Factors
- Interim clinical data from 31 patients across trials — small sample, not randomized; results may not replicate in Phase 3.
- AlloNK is unapproved; regulatory path uncertain; safety/efficacy risks in larger populations.
- Competition from multiple CAR T and NK cell therapies in autoimmune indications (Kyverna, BMS, Fate, etc.).
- Cash runway not disclosed; dilutive financing possible as a clinical-stage company without revenue.
- Historical calibration shows score-8 reports on this ticker have low observed P&L win rate (34%) at T+20, though the small n and biotech event-driven volatility limit reliability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297953 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access